| 1.795 -0.005 (-0.28%) | 04-16 12:33 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.18 | 1-year : | 2.3 |
| Resists | First : | 1.86 | Second : | 1.97 |
| Pivot price | 1.82  |
|||
| Supports | First : | 1.7 | Second : | 1.41 |
| MAs | MA(5) : | 1.8 | MA(20) : | 1.82 |
| MA(100) : | 1.76  |
MA(250) : | 2.1 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 22.4 |
D(3) : | 24.5 |
| RSI | RSI(14): 48.3 | |||
| 52-week | High : | 3.45 | Low : | 1.15 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IMAB ] has closed above bottom band by 25.5%. Bollinger Bands are 81.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 22 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.84 - 1.84 | 1.84 - 1.85 |
| Low: | 1.76 - 1.78 | 1.78 - 1.79 |
| Close: | 1.78 - 1.8 | 1.8 - 1.82 |
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Tue, 16 Apr 2024
I-Mab (NASDAQ:IMAB) Short Interest Update - MarketBeat
Mon, 15 Apr 2024
I-Mab Announces CMO Transition, Interim Successor Named - TipRanks.com - TipRanks
Sun, 14 Apr 2024
I-Mab (NASDAQ:IMAB) Rating Reiterated by Needham & Company LLC - Defense World
Fri, 12 Apr 2024
I-Mab's (IMAB) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Fri, 05 Apr 2024
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference - PR Newswire
Tue, 02 Apr 2024
I-Mab Announces Closing of the Divestiture of Business Operations in China - Longview News-Journal
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 81 (M) |
| Held by Insiders | 1.226e+008 (%) |
| Held by Institutions | 1 (%) |
| Shares Short | 1,070 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -7 % |
| Return on Assets (ttm) | 62.7 % |
| Return on Equity (ttm) | -23.2 % |
| Qtrly Rev. Growth | 2.764e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -55.88 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -3.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.04 |
| Price to Cash Flow | 0.09 |
| Dividend | 0 |
| Forward Dividend | 1.17e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|